Rezolute's Ersodetug Shows Early Promise in Tumor Hyperinsulinism Trial
Event summary
- Rezolute's Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism is 50% enrolled, with 6 of 8 participants meeting the primary endpoint.
- Topline results for the fully enrolled study are expected in the second half of 2026.
- Ersodetug has been well-tolerated with no drug-related adverse events reported to date.
- One participant withdrew due to cancer progression and was counted as a non-responder.
The big picture
Rezolute's interim data for ersodetug in tumor hyperinsulinism suggests potential as a universal treatment for refractory hypoglycemia. The company aims to leverage these results to navigate regulatory hurdles and expand into a market with significant unmet needs. The success of ersodetug could redefine treatment options for patients with rare and acquired forms of hyperinsulinism.
What we're watching
- Regulatory Pathway
- Whether Rezolute can secure FDA approval for ersodetug in congenital HI despite previous trial setbacks.
- Clinical Efficacy
- The pace at which ersodetug demonstrates consistent efficacy across different tumor types in hyperinsulinism.
- Market Potential
- How Rezolute positions ersodetug as a universal treatment for refractory hypoglycemia in both congenital and acquired forms.